Finance

Lists
300261:SHE
ABA Chemicals Corp
CNÂ¥4.85
-0.82%
(-0.040) 1D
Sep 14, 3:04:49 PM GMT+8  ·   CNY
All symbols
SymbolPriceChange% Change
Generating top insights for 300261...
Open
CNÂ¥4.91
High
CNÂ¥5.09
Low
CNÂ¥4.80
Mkt. cap
4.71B
Avg. vol.
19.45M
Volume
16.20M
52-wk high
CNÂ¥8.66
52-wk low
CNÂ¥4.27
EPS
-CNÂ¥0.33
Shares outstanding
963.31M
No. of employees
1K
Open
CNÂ¥4.91
High
CNÂ¥5.09
Low
CNÂ¥4.80
Mkt. cap
4.71B
Avg. vol.
19.45M
Volume
16.20M
52-wk high
CNÂ¥8.66
52-wk low
CNÂ¥4.27
EPS
-CNÂ¥0.33
Shares outstanding
963.31M
No. of employees
1K
Profile
ABA Chemicals, also known as Abachem, is a Chinese chemical manufacturing company headquartered in Taicang. The company was founded in 2006 as Suzhou ABA Chemicals, and is traded on the Shenzhen Stock Exchange as 300261. The company provides contract development and manufacturing services to the pharmaceutical, biotechnological, and agrochemical industries. It offers various services for the production of fine chemicals; intermediates; and active pharmaceutical ingredients. The company also provides unnatural amino acids, pyrazoles, triazoles, and azaindoles, as well as producing an intermediate of API Levetiracetam for the treatment of epilepsy. The company is also involved in pesticide manufacturing intermediates, and acquired the Chinese firm Shanghai Puyi Chemical to consolidate its position in this market. It also acquired Amino Chemicals, a pharmaceutical API intermediate manufacturer and member of the Dipharma Group, in 2017; Amino is based on Malta and was established in 1992. ABA and Dipharma began a working partnership in the 1980s, which provided Dipharma access to the Chinese pharmaceutical market. Wikipedia
About ABA Chemicals Corp
CEO-
Employees1.2K
FoundedJan 13, 2006
Headquarters-
SectorSpeciality chemicals
Previous reportsAll values in CNY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in CNY
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
334.69M
310.82M
303.59M
293.25M
Cost of goods sold
248.45M
300.89M
286.91M
290.74M
Cost of revenue
248.45M
300.89M
286.91M
290.74M
Research and development expenses
29.18M
28.68M
20.19M
23.49M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
48.48M
37.47M
41.02M
42.09M
Operating expense
81.42M
103.89M
62.77M
66.36M
Total operating expenses
329.87M
404.78M
349.68M
357.10M
Operating income
4.82M
-93.96M
-46.09M
-63.86M
Other non operating income
15.52M
-16.13M
-10.85M
-38.01M
EBT including unusual items
-2.79M
-177.93M
-73.15M
-115.16M
EBT excluding unusual items
-1.61M
-124.19M
-66.74M
-92.06M
Income tax expense
-3.44M
-6.13M
-14.24M
-13.04M
Effective tax rate
123.57%
3.45%
19.47%
11.32%
Other operating expenses
2.79M
-849.91K
2.71M
-370.40K
Net income
1.75M
-152.59M
-57.58M
-101.81M
Net profit margin
0.52%
-49.09%
-18.97%
-34.72%
Earnings per share
-
-
-
-
Interest and investment income
5.04M
-
568.87K
10.37M
Interest expense
-9.72M
-15.90M
-10.37M
-568.87K
Net interest expenses
-4.68M
-15.90M
-9.80M
9.80M
Depreciation and amortization charges
-
-
-
-
EBITDA
38.18M
-59.20M
-11.33M
-29.90M
Gain or loss from assets sale
110.13K
-161.52K
-
-258.93K
AI content may include mistakes. Learn more
Google apps